This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Evidence for a Dose-Response Effect

Paul F. Pinsky, MPH; Eugene S. Hurwitz, MD; Lawrence B. Schonberger, MD, MPH; Walter J. Gunn, PhD

JAMA. 1988;260(5):657-661.

Abstract
Data collected from the Public Health Service Main Study of Reye's Syndrome and Medications were analyzed to assess the relationship between the development of Reye's syndrome and the dose of aspirin received during the antecedent respiratory or chickenpox illness. Among those exposed to aspirin, case-patients were found to have received greater average daily and maximum daily doses of aspirin and greater doses of aspirin on the first four days of the antecedent illness (median, 25.1 mg/kg; 33.0 mg/kg; and 65.4 mg/kg; respectively) than did controls (median, 14.5 mg/kg; 19.0 mg/kg; and 27.0 mg/kg; respectively). The excess risk associated with increasing aspirin doses was due primarily to intermediate levels of dose (eg, 15 to 27 mg/kg per day) rather than higher levels (>27 mg/kg per day). The dose difference between exposed case-patients and controls was greatest on days 3 and 4 of the antecedent illness.

(JAMA 1988;260:657-661)

Author Affiliations
From the Division of Viral Diseases, Center for Infectious Diseases, Centers for Disease Control, Atlanta.

Footnotes
Reprint requests to Centers for Disease Control, Bldg 6, Room 119, Atlanta, GA 30333 (Mr Pinsky).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacological Characterization of N-tert-Butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a Novel Thromboxane A2 Receptor Antagonist and Thromboxane Synthase Inhibitor in a Rat Model of Arterial Thrombosis and Its Effects on Bleeding Time
Dogne et al.
J. Pharmacol. Exp. Ther. 2004;309:498-505.
ABSTRACT | FULL TEXT  

Reassessing Reye Syndrome
Chow et al.
Arch Pediatr Adolesc Med 2003;157:1241-1242.
FULL TEXT  

The Drug Hypersensitivity Syndrome: What Is the Pathogenesis?
Sullivan and Shear
Arch Dermatol 2001;137:357-364.
FULL TEXT  

Routine influenza vaccination for healthy children---old concept, new technologies
BEYER
Arch. Dis. Child. 2000;83:461-462.
FULL TEXT  

Pediatric Ibuprofen Use Increases While Incidence of Reye's Syndrome Continues to Decline
Prior et al.
CLIN PEDIATR 2000;39:245-247.
 

Reye's Syndrome in the United States from 1981 through 1997
Belay et al.
NEJM 1999;340:1377-1382.
ABSTRACT | FULL TEXT  

Reye Syndrome Surveillance--United States, 1989
JAMA 1991;265:960-960.
 

Reye Syndrome Surveillance-- United States, 1987 and 1988
JAMA 1989;261:3520-3523.
 

ASPIRIN AND REYE'S SYNDROME: A DOSE-RESPONSE RELATION
JWatch General 1988;1988:3-3.
FULL TEXT